Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Widespread Monoaminergic Dysregulation of Both Motor and Non-Motor Circuits in Parkinsonism and Dyskinesia.

Engeln M, De Deurwaerdère P, Li Q, Bezard E, Fernagut PO.

Cereb Cortex. 2015 Sep;25(9):2783-92. doi: 10.1093/cercor/bhu076. Epub 2014 Apr 25.

PMID:
24770706
2.

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Fidalgo C, Ko WK, Tronci E, Li Q, Stancampiano R, Chuan Q, Bezard E, Carta M.

Neuroscience. 2015 Jul 9;298:389-96. doi: 10.1016/j.neuroscience.2015.04.027. Epub 2015 Apr 20.

PMID:
25907446
3.

Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity.

Nicholas AP, Buck K, Ferger B.

Neurosci Lett. 2008 Oct 10;443(3):204-8. doi: 10.1016/j.neulet.2008.07.039. Epub 2008 Jul 19.

PMID:
18657593
4.

Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.

Berton O, Guigoni C, Li Q, Bioulac BH, Aubert I, Gross CE, Dileone RJ, Nestler EJ, Bezard E.

Biol Psychiatry. 2009 Sep 15;66(6):554-61. doi: 10.1016/j.biopsych.2009.04.005. Epub 2009 May 28.

5.

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.

Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):446-54. doi: 10.1016/j.pnpbp.2009.12.011. Epub 2009 Dec 16.

PMID:
20026151
6.

Nur77 mRNA levels and L-Dopa-induced dyskinesias in MPTP monkeys treated with docosahexaenoic acid.

Mahmoudi S, Samadi P, Gilbert F, Ouattara B, Morissette M, Grégoire L, Rouillard C, Di Paolo T, Lévesque D.

Neurobiol Dis. 2009 Oct;36(1):213-22. doi: 10.1016/j.nbd.2009.07.017. Epub 2009 Jul 25.

7.

Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.

Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM.

J Pharmacol Exp Ther. 2011 Feb;336(2):423-30. doi: 10.1124/jpet.110.169532. Epub 2010 Oct 21.

PMID:
20966038
8.

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

J Neurosci. 2011 May 11;31(19):7190-8. doi: 10.1523/JNEUROSCI.1171-11.2011.

9.

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.

Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B.

Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23. doi: 10.1016/j.parkreldis.2014.05.007. Epub 2014 May 22.

PMID:
25172125
10.

5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.

Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM.

Neurobiol Aging. 2012 Jan;33(1):194.e5-15. doi: 10.1016/j.neurobiolaging.2010.04.035. Epub 2010 Jun 18.

PMID:
20561716
11.
12.

Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.

Riahi G, Morissette M, Parent M, Di Paolo T.

Eur J Neurosci. 2011 May;33(10):1823-31. doi: 10.1111/j.1460-9568.2011.07675.x. Epub 2011 Apr 19.

PMID:
21501255
13.

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

Bézard E, Muñoz A, Tronci E, Pioli EY, Li Q, Porras G, Björklund A, Carta M.

Neurosci Res. 2013 Dec;77(4):242-6. doi: 10.1016/j.neures.2013.10.002. Epub 2013 Oct 14.

PMID:
24135129
14.
15.
16.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
17.

Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.

Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.

Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2.

PMID:
19576910
18.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
19.

Effects of L-tryptophan on L-DOPA-induced dyskinesia in the L-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease.

Ko WK, Li Q, Bezard E.

Neurosci Lett. 2014 Apr 30;566:72-6. doi: 10.1016/j.neulet.2014.02.027. Epub 2014 Feb 23.

PMID:
24572591
20.

Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.

Stockwell KA, Scheller D, Rose S, Jackson MJ, Tayarani-Binazir K, Iravani MM, Smith LA, Olanow CW, Jenner P.

Exp Neurol. 2009 Oct;219(2):533-42. doi: 10.1016/j.expneurol.2009.07.011. Epub 2009 Jul 18.

PMID:
19619533

Supplemental Content

Support Center